Abstract
Functional. The functional approach to receptor classification was pioneered by Ahlquist (1948), who demonstrated that adrenoceptors could be subclassified into α-and β-subtypes on the basis of the rank order of potency of a series of cathecholamines. Although the power of this approach was not immediately acknowledged, it gradually became accepted, and has now been utilised in the classification of most if not all known hormone receptors. It has been of crucial importance in the classification of prostanoid receptors, leading to the now generally accepted conclusion that there are receptors specific for each of the naturally occurring prostanoids, and that there are subtypes of at least one of these (Coleman et al., 1994b). The first tentitive steps towards the classification of prostanoid receptors were made by Pickles in 1967, who reported that a range of different prostanoid analogues exhibited different rank orders of agonist potency in a range of different tissues. This report was followed by those of Andersen and Ramwell (1974), Andersen et al. (1980) and Gardiner and Collier (1980), who provided further evidence for distinct rank orders of prostanoid agonist potency in different systems both in vitro and in vivo. However, it was the work of Kennedy et al. (1982) that provided the basis for the classification of prostanoid receptors that is now universally accepted (see Coleman et al., 1994b, Table 1). This classification states that there are five basic classes of receptor, DP, EP, FP, IP and TP, with subdivision of the EP class into four subtypes, EP1, EP2, EP3 and EP4. As yet, there is no conclusive evidence of subtypes of any of the other four classes, but it seems unlikely that such subdivision is restricted to EP-receptors, and it has been suggested that there are subtypes of both DP and TP-receptors. Further subdivision of EP-receptors is now apparent following the discovery that there are a number of isoforms of the EP3-receptor class (Namba et al., 1993).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Abramowitz, M., Boie, Y., Nguren, T., Rushmore, T.H., Baynes, M.A., Metters, K.M., Slipetz, D.M. and Grygorczyk, R., 1994, Cloning and expression of a cDNA for the human prostanoid FP receptor. J. Biol Chem., 269: 2632–2636.
Ahlquist, R.R, 1948, A study of the adrenotropic receptors. Am. J. Physiol., 153: 586–600.
Alvarez, R., Eglen, R.M., Chang, L.F., Bruno, J.J., Artis, D.R., Kluge, A.F. and Whiting, R.L., 1991, Stimulation of prostaglandin D2 receptors on human platelets by analogs of prostacyclin. Prostaglandins, 42:105–119.
An, S., Yang, J., Xia, M. and Goetzl, E.J., 1993, Cloning and expression of the EP2 subtype of human receptors for prostaglandin E2. Biochem. Biophys. Res. Commun., 197: 263–270.
Andersen, N.H., Eggerman, T.L. Harker, L.A, Wilson, C.H. and De, B., 1980, On the multiplicity of platelet prostaglandin receptors. 1. Evaluation of competitive antagonism by aggregometry. Prostaglandins, 19:711–734.
Andersen, N.H. and Ramwell, P.W., 1974, Biological aspects of prostaglandins. Arch. Intern. Med., 133: 30–50.
Birrell, G.J. McQueen, D.S., Iggo, A., Coleman, R.A. and Grubb B.D., 1991, PGI2-induced sensitization of articular mechanonociceptors. Neurosci Lett., 124: 5–8.
Boie, Y., Rushmore, T.H., Darmon-Goodwin, A., Grygorczyk, R. Slipetz, D.M. Metters, K.M. and Abramovitz, M., 1994, Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem, 269: 12173–12178.
Breyer, M.D., Jacobson, H.R., Davis, L.S. and Breyer, R.M., 1993, In situ hybidization and localization of mRNA for the rabbit prostaglandin EP3 receptor. Kidney Int., 43: 1372–1378.
Bunce, K.T. Clayton, N.M., Coleman, R.A., Collington, E.W., Finch, H., Humphrey, P.P.A., Reeves, J.J., Sheldrick, R.L.G. and Stables, R., 1990, GR63799X-a novel prostanoid with selectivity for EP3 receptors. Adv. Prostaglandin Thromboxane Leukotriene Res., 21: 379–382.
Bygdeman, M. Prostaglandins for termination of pregnancy.In: Therapeutic Applications of Prostaglandins. ed. J. Vane & J. O’Grady, Edward Arnold, Boston (1993), pp85-91.
Caldwell, A.G., Harris, C.J., Stepney, R. and Whittaker, N., 1979, Hydantoin prostaglandin analogues, potent and selective inhibitors of platelet aggregation. J. Chem. Soc. Chem. Comm., 101: 561–562.
Coleman, R.A., Grix, S.P., Head, S.A., Louttit, J.B., Mallett, A. and Sheldrick, R.L.G., 1994a, A novel inhibitory receptor in piglet saphenous vein. Prostaglandins, 47: 151–168.
Coleman, R.A., Kennedy, I., Humphrey, P.P.A., Bunce, K. & Lumley, P. Prostanoids and their receptors. In: Comprehensive Medicinal Chemistry Vol. 3. Membranes and Receptors ed. J.C. Emmett Pergamon Press, Oxford.(1990), pp643–714
Coleman, R.A., Kennedy, I. and Sheldrick, R.L.G., 1987, Evidence for the existence of three subtypes of PGE2-senstive (EP-) receptors. Br. J. Pharmacol., 91: 323P.
Coleman, R.A., Mallett, A. and Sheldrick, R.L.G., 1995, EP4-receptors and cyclic AMP pig venous smooth muscle: evidence with agonists and the EP4-antagonist, AH 22921. Adv. Prostaglandin Thromboxane Leukotriene Res. 23: 241–246.
Coleman, R.A., Smith, W.L. and Narumiya, S., 1994b, Classification of prostanoid receptors: properties, distribution and structure of the receptors and their subtypes. Pharmacol. Rev., 46: 205–229.
Cooper, B. and Ahern, D., 1979, Characterisation of the platelet prostaglandin D2 receptor. J. Clin. Invest., 64: 586–590.
Cooper, B., Schafer, A.I., Puchalsky, D. and Handin, R.I., 1979, Desensitisation of prostaglandin-activated platelet adenylate cyclase. Prostaglandins, 17: 561–571.
Funk, C.D., Furci, L., FitzGerald, G.A., Grygorczyk, R., Rochette, C., Bayne, M.A., Abramovitz, M., Adam, M., and Metters, K.M., 1993, Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J. Biol. Chem., 268: 26767–26772.
Gardiner, P.J., 1986, Characterisation of prostanoid relaxant /inhibitory receptors (ψ) using a highly selective agonist, TR4979. Br. J. Pharmacol., 87: 45–56.
Gardiner, P.J. and Collier, H.O.J., 1980, Specific receptors for prostaglandins in airways. Prostaglandins, 19: 819–841.
Halushka, P.V., Mais, D.E., Mayeux, P.R. and Morinelli, T.A., 1989, Thromboxane, prostaglandin and leukotriene receptors. Ann. Rev. Pharmacol. Toxicol., 29: 213–239.
Harris, D.N., Hedberg, A., Phillips, M.B., Michel, I.M., Goldenberg, H.J. and Liu, E.C.-K., 1987, 7-Oxabicycloheptane analogs: modulators of the arachidonate cascade. Adv. Prostaglandin Thromboxane Leukotriene Res., 17: 482–486.
Hirata, M., Hayashi, Y., Ushikubi, F., Yokota, Y., Kageyama, R., Nakanishi, S. and Narumiya, S., 1991, Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature, 349: 617–620.
Hirata, M. Kakizuka, A., Aizawa, M., Ushikubi, F. and Narumiya, S., 1994, Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc. Nat. Acad. Sci., 91: 11192–11196.
Honda, A., Sugimoto, Y., Namba, T., Watabe, A., Irie, A., Negishi, M., Narumiya, S. and Ichikawa, A., 1993, Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J. Biol. Chem., 268: 7759–7762.
Ito, S., Okuda, E., Sugama, K., Negishi, M. and Hayaishi, O., 1990, Evaluation of ZK110841 and AH6809, an agonist and an antagonist of prostaglandin DP-receptors on human platelets, with a PGD2-responsive cell line from bovine embryonic trachea. Br. J. Pharmacol., 99: 13–14.
Jackson, P.S. and Jessup, R., 1984, Secondary pharmacological properties of prostaglandins. Vet. Rec., 114: 168.
Kennedy, I., Coleman, R.A., Humphrey, P.P.A., Levy, G.P. and Lumley, P., 1982, Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins 24: 667–689.
Kitanaka, J., Hasimoto, H., Sugimoto, Y., Negishi, M., Aino, H., Gotoh, M., Ichikawa, A. and Baba, A., 1994, Cloning and expression of a cDNA for rat prostaglandin PGF2α receptor. Prostaglandins, 48: 31–41.
Lake, S., Gullberg, H., Wahlqvist, J., Sjogren, A.-M., Kinhult, A., Lind, P., Hellström-Lindahl, E. and Stjernschantz, J., 1994, Cloning of the rat and human prostaglandin F2α receptors and the expression of the rat prostaglandin F2α receptor. FEBS Let., 355: 317–325.
Linet, O. Prostaglandins in erectile dysfunction. In: Therapeutic Applications of Prostaglandins, ed. J. Vane & J. O’Grady, Edward Arnold, Boston (1993), PP105–121.
Mais, D.E., Saussy, D.L., Chaikhouni, J.R., Kochel, P.J., Knapp, D.R., Hamanaka, N. and Halushka, P.V., 1985, Pharmacological characterisation of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors. J. Pharmacol. Exp. Ther., 233: 418–424.
Malmsten, C., 1976, Some biological effects of prostaglandin analogs. Life Sci., 18: 169–176.
Merritt, J.E., Hallam, T.J., Brown, A.M., Boyfield, I., Cooper, D.G., Hickey, D.M.B., Jaxa-Chamiec, A.A., Kaumann, A.J., Keen, M., Kelly, E., Kozlowski, U., Lynham, J.A., Moores, K.E., Murray, M.J. and Rink, T.J., 1991, Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor. Br. J. Pharmacol., 102: 251–259.
Moncada, S., 1982, Biological importance of prostacyclin. Br. J. Pharmacol., 76: 3–31.
Morrow, J.D., Hill, K.E., Burk, R.F., Nammour, T.M., Badr, K.F. and Roberts L.J., 1990, A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclo-oxygenase, free radical-catalysed mechanism. Proc. Nat. Acad. Sci., 87: 9383–9387.
Namba, T., Oida, H., Sugimoto, Y., Kakizuka, A., Negishi, M., Ichikawa, A. and Narumiya, S., 1994, cDNA cloning of a mouse prostacyclin receptor; multiple signalling pathways and expression in thymic medulla. J. Biol. Chem., 269: 9986–9992.
Namba, T., Sugimoto, Y., Hirata, M., Hayashi, Y., Honda, A., Watabe, A., Negishi, M., Ichikawa, A. and Narumiya, S., 1992, Mouse thromboxane A2 receptor: cDNA cloning, expression and northern blot analysis. Biochem Biophys Res Commun, 184: 1197–1203.
Namba, T., Sugimoto, Y, Negishi, M., Irie, A., Ushikubi, F., Kakizuka, A., Ito, S., Ichikawa, A., and Narumiya, S., 1993, Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature, 365: 166–170.
Niais, A.T., Vardey, C.J., Denyer, L.H., Thomas, M., Sparrow, S J., Shepherd, G.D. and Coleman, R.A., 1993, AH13205, a selective prostanoid EP2-receptor agonist. Cardiovasc. Drug Rev., 11: 165–179.
Nüsing, R.M., Hirata, M., Kakizuka, A., Eki, T., Ozawa, K. and Narumiya, S., 1993, Characterization and chromosomal mapping of the human thromboxane A2 receptor gene. J. Biol. Chem., 268: 25253–25259.
Ogletree, M.L. and Allen, G.T., 1992, Interspecies differences in thromboxane receptors: studies with thromboxane receptor antagonists in rat and guinea-pig smooth muscles. J. Pharmacol. Exp. Then, 260: 789–794.
Pickles, V.R. The myometrial actions of six prostaglandins: consideration of a receptor hypothesis. Nobel Symposium, Vol 2: Prostaglandins. Bergström, S., Samuelsson, B. Almquist & Wicksell, Stockholm (1967) pp79–83.
Raychowdhury, M.K., Yukawa, M., Collins, L.J., McGrail, S.H., Kent, K.C. and Ware, J.A., 1994, Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane receptor. J. Biol. Chem., 269: 19256–19261.
Reeves, J.J., Bunce, K.T., Sheldrick, R.L.G. and Stables, R., 1988, Evidence for the PGE receptor subtype mediating inhibition of acid secretion in the rat. Br. J. Pharmacol., 95: 805P.
Regan, J.W., Bailey, T.J., Donello, J.E., Pierce, K.L., Pepperl, D.J., Zhang, D., Kedzie, K.M., Fairbairn, C.E., Bogardus, A.M., Woodward, D.F. and Gil, D.W., 1994, Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxy termini. Br. J. Pharmacol., 112: 377–385.
Regan, J.W., Bailey, T.J., Pepperl, D.J., Pierce, K.L., Bogardus, A.M., Donello, J.E., Fairbairn, C.E., Kedzie, K.M., Woodward, D.F. and Gil, D.W., 1994, Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol. Pharmacol., 46: 213–220.
Robertson, P.R., 1986, Characterization and regulation of prostaglandin and leukotriene receptors: an overview. Prostaglandins, 31: 395–411.
Senior, J., Sangha, R., Baxter, G.S., Marshall, K. and Clayton, J.K., 1992, In vitro characterization of prostanoid FP-, DP-, IP-and TP-receptors in the non-pregnant human myometrium. Br. J. Pharmacol., 107: 215–221.
Sewing, K.-F.R. and Beinborn, M., 1990, Eicosanoid receptors of the gastrointestinal tract. Adv. Prostaglandin Thromboxane Leukotriene Res., 20: 138–145.
Simon, B., Kather, H. and Kommereil, B., 1980, Activation of human colonic mucosal adenylate cyclase by prostaglandins. Adv. Prostaglandin Thromboxane Res. 8: 1617–1620.
Sinzinger, H. Prostaglandins in ischaemic peripheral vascular disease. In: Therapeutic Applications of Prostaglandins, ed. J. Vane & J. O’Grady, Edward Arnold, Boston (1993), PP209–218.
Smith, G.C.S., Coleman, R.A. and McGrath, J.C., 1994, Characterisation of dilator prostanoid receptors in fetal rabbit ductus arteriosus. J. Pharmacol. Exp. Ther., 271: 390–396.
Stjernschantz, J., 1995, Prostaglandins as ocular hypotensive agents; development of an analogue for glaucoma treatment. Adv. Prostaglandin Thromboxane Leukotriene Res., 23: 63–68.
Strong, P., Coleman, R.A. and Humphrey, P.P.A., 1992, Prostanoid-induced inhibition of lipolysis in rat isolated adipocytes: probable involvement of EP3 receptors. Prostaglandins, 43: 559–566.
Sugimoto, Y., Hasumoto, K., Namba, T., Irie, A., Katsuyama, M., Negishi, M., Kakizuka, A., Narumiya, S. and Ichikawa, A., 1994, Cloning and expression of a cDNA for mouse prostglandin F receptor. J. Biol. Chem. 269: 1356–1360.
Sugimoto, Y., Namba, T., Honda, A., Hayashi, Y., Negishi, M., Ichikawa, A. and Narumiya, S., 1992, Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. J. Biol. Chem., 267: 6463–6466.
Takeuchi, K., Abe, T., Takahashi, N. and Abe, K., 1993, Molecular cloning and intrarenal localization of rat prostaglandin E2 receptor EP3 subtype. Biochem. Biophys. Res. Commun., 194: 885–891.
Thierauch, K.-H., Stürzebecher, C. St., Schillinger, E., Rehwinkel, H., Radüchel, B., Skuballa, W. and Vörbruggen, H., 1988, Stable 9β-or 11α-halogen-15-cyclohexyl-prostaglandins with high affinity to the PGD2 receptor. Prostaglandins, 35: 853–868.
Town, M.H. Casals-Stenzel, J. and Schillinger, E., 1983, Pharmacological and cardiovascular properties of a hydantoin derivative, BW245C, with high affinity and selectivity for PGD2 receptors. Prostaglandins, 25: 13–28.
Watabe, A., Sugimoto, Y., Honda, A., Irie, A., Namba, T., Negishi, M., Ito, S., Narumiya, S. and Ichikawa, A., 1993, Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J. Biol. Chem., 268: 20175–20178.
Witherspoon, D.M., Lamond, D.R., Thompson, F.N. and Stevenson, W., 1975, Efficacy of a prostaglandin analogue in reproduction in the cycling mare. Theriogenology, 3: 21–30.
Woodward, D.F., Fairbairn, C.E., Krauss, A.H.-P., Lawrence, R.A. and Protzman, C.E., 1995, Radioligand binding analysis of receptor subtypes in two FP receptor preparations that exhibit different functional rank orders of potency in response to prostaglandins. J. Pharmacol. Exp. Ther., 273: 285–291.
Woodward, D.F. and Lawrence, R.A., 1994, Prostanoid induced Ca2+ signals in Swiss 3T3 cells are mediated by a single (FP) receptor. Biochem. Pharmacol., (in press).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Coleman, R.A. (1996). Prostanoid Receptors. In: Folco, G.C., Samuelsson, B., Maclouf, J., Velo, G.P. (eds) Eicosanoids. NATO ASI Series, vol 283. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-0200-9_14
Download citation
DOI: https://doi.org/10.1007/978-1-4899-0200-9_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-0202-3
Online ISBN: 978-1-4899-0200-9
eBook Packages: Springer Book Archive